breast cancer and glp 1 for Glucagon-like peptide 1 receptor agonists cancer risk: advancing precision GLP-1 Receptor Agonists in Breast – Efficacy of GLP-1 Receptor Agonists

Real-world data from compounding pharmacy patients using semaglutide show an average systolic drop of 48 mmHg within 12 weeks, with some individuals experiencing reductions exceeding 15 mmHg

Conceio-Furber and colleagues, in Frontiers in Endocrinology, lay out how turning on the glucagon receptor lifts energy use enough to open a calorie deficit even without any extra appetite suppression

They reduce appetite, slow gastric emptying, and improve blood-sugar control

The clinical benefits of finerenone on cardiovascular and kidney events are also unlikely affected by combination therapy with GLP-1RA or SGLT2i, however, clinical evidence on additive effects of finerenone in combination with GLP-1RA or SGLT2i are still limited [56, 57]

Both products should be taken with water

This supplement can be particularly beneficial for people experiencing the effects of aging, including reduced energy levels and changes in body composition